Research Question
What specific oncology workflow question does Multi-Center Collaboration Controls try to solve? This research brief studies how OncogenTime can turn fragmented clinical context into a reviewable product workflow around collaboration spaces, organization-level permissions, research workflows, and security boundaries for multi-center programs. The question is intentionally practical: can the platform help a clinician, researcher, or care team understand the case journey faster while preserving source context, uncertainty, and human review?
Why It Matters
Multi-Center Collaboration Controls matters because oncology work is rarely a single event. Diagnosis, therapy, response, toxicity, recurrence, surveillance, and follow-up all change over time, and the value of a decision-support environment depends on whether teams can see those changes together. For doctors, this reduces time spent rebuilding context. For researchers, it creates cleaner research intelligence. For patient tracking and follow-up teams, it keeps unresolved questions and longitudinal care signals visible.
Product Investigation
OncogenTime investigates this workstream as a product module inside the oncology intelligence workspace. The prototype direction includes timeline views, evidence cards, reviewer notes, status labels, source-aware summaries, and dashboard-ready exports. The product is designed to help users inspect documented information and prepare multidisciplinary discussion, not to generate autonomous clinical decisions.
Data / Journey Model
The journey model uses seven core data domains: diagnosis, therapy, response, toxicity, recurrence, surveillance, and follow-up. Diagnosis anchors the clinical context. Therapy captures regimen history and timing. Response records documented clinical, imaging, or report-based change. Toxicity captures safety and tolerability context. Recurrence tracks documented or suspected disease return. Surveillance stores monitoring intervals and related questions. Follow-up preserves unresolved issues, future tasks, and continuity notes.
Status and Boundary
Status: enterprise feature investigation. This page is classified under the Standalone diagnosis claims research track completed in a university research context. The scope evaluates how standalone diagnostic-claim boundaries could be documented, reviewed, and governed. It is not medical advice, not a deployed diagnostic system, not regulatory clearance, not a clinical validation claim, and not a substitute for clinician judgment. The intended positioning remains research-stage decision-support with clinician-in-the-loop review.
Future Work
Future work includes FHIR-aligned data mapping, structured clinician feedback loops, anonymized cohort analysis, dashboard export for clinical and research review, and validation studies. Those next steps would evaluate data completeness, source traceability, workflow usefulness, safety language, and reviewer agreement before any stronger clinical or regulatory positioning is considered.
